Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13547569 | 0.88 | TRPC5 (0.49) | SIGMAR1KMT2AMEN1POLBLMNA | |
| SCHEMBL26964867 | 0.85 | KMT2A (0.46) | SIGMAR1KMT2AMEN1POLBLMNA | |
| SCHEMBL13283790 | 0.85 | SIGMAR1 (0.53) | SIGMAR1KMT2AMEN1POLBTHRA | |
| SCHEMBL13841388 | 0.81 | TSHR (0.60) | KMT2AMEN1POLBLMNAKDM4E | |
| SCHEMBL20715468 | 0.81 | ALDH1A1 (0.48) | SIGMAR1KMT2AMEN1POLBLMNA | |
| SCHEMBL8245365 | 0.80 | KMT2A (0.65) | SIGMAR1KMT2AMEN1THRBLMNA | |
| SCHEMBL3222264 | 0.78 | CD274 (0.55) | KMT2AMEN1LMNAKDM4EABL1 | |
| SCHEMBL5549334 | 0.78 | MEN1 (0.68) | SIGMAR1KMT2AMEN1POLBLMNA | |
| SCHEMBL4185225 | 0.78 | LMNA (0.59) | KMT2AMEN1LMNAKDM4EHIF1A | |
| SCHEMBL13034201 | 0.78 | SIGMAR1 (0.58) | SIGMAR1KMT2AMEN1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | SIGMAR1 837/4885KMT2A 3970/4885MEN1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.